Narcolepsy Market is Segmented By Diagnosis Type (Polysomnography, Multiple Sleep Latency Test, Hypocretin/Orexin Level Test), By Treatment Type (Stim....
Market Size in USD
CAGR9.3%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 9.3% |
Market Concentration | High |
Major Players | Jazz Pharmaceuticals plc, Takeda Pharmaceutical Company, Teva Pharmaceuticals USA, Inc., Vanda Pharmaceuticals, Kyowa Kirin, Inc. |
The Narcolepsy Market is estimated to be valued at USD 2.53 Billion in 2024 and is expected to reach USD 4.68 Billion by 2031, growing at a compound annual growth rate (CAGR) of 9.3% from 2024 to 2031. The increasing prevalence of sleep disorders such as obstructive sleep apnea and increasing awareness about diagnosis and treatment of narcolepsy are contributing to the growth of the market.
The narcolepsy market is expected to witness lucrative growth over the forecast period. Technological advancements in developing novel therapies and drugs as well as growing research activities on identifying the genetic mutations that lead to narcolepsy are anticipated to create new opportunities. Furthermore, increasing healthcare expenditures and improved access to diagnosis and treatment in developing nations will further aid the expansion of the narcolepsy market during the analysis timeframe.